Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Brian J Scott, MD
- Phone Number: (650) 723-6409
- Email: bjscott@stanford.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94305
- Stanford Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- >/= 18 years-old
- Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or
- Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers
- >/= 6 months from the date of CAR-T infusion
- Fluent in English
- Able to attend and participate in in-person testing (Arm I)
- Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II)
Exclusion Criteria:
- Concurrent enrollment in a CAR-T therapeutics research study
- Unable to be present for the scheduled testing
- Unable to participate in testing due to severe cognitive or physical limitation
- Actively receiving chemotherapy
- Progressive cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Neuropsychological testing
Participants will take neuropsychological testing in-person or via telehealth video
|
Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of patients who complete neuropsychological testing in the post-CAR-T adult population
Time Frame: 6 months
|
6 months
|
|
Number of patients who complete telehealth neuropsychological testing in the post-CAR-T adult
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wechsler Test of Adult Reading WTAR Neuropsychological testing
Time Frame: Baseline
|
The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.
|
Baseline
|
|
Hopkins Verbal Learning Test HVLT
Time Frame: Baseline
|
The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.
|
Baseline
|
|
Controlled Oral Work Association Test COWAT
Time Frame: Baseline
|
The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.
|
Baseline
|
|
Trails A and B (Oral Trails)
Time Frame: Baseline
|
The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.
|
Baseline
|
|
Digit Span
Time Frame: Baseline
|
The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.
|
Baseline
|
|
Clock Drawing Test
Time Frame: Baseline
|
The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data.
|
Baseline
|
|
Short form of Quality of Life SF-36
Time Frame: Baseline
|
Items from the SF36 (Short Form 36) survey
|
Baseline
|
|
General Anxiety Disorder Assessment GAD-7
Time Frame: Baseline
|
Assesses anxiety symptoms The following cut-offs correlate with level of anxiety severity: Score 0-4: Minimal Anxiety, Score 5-9: Mild Anxiety, Score 10-14: Moderate Anxiety, Score greater than 15: Severe Anxiety |
Baseline
|
|
Patient Health Questionnaire PHQ9
Time Frame: Baseline
|
Assesses depressive symptoms PHQ-9 Score 0 - 4 None, Mild= 5 - 9 , Moderate=10 - 14 , Moderately Severe=15 - 19 , Severe=20 - 27
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Brian Scott, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB-56813
- CCT5069 (Other Identifier: OnCore)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.